Global Information
회사소개 | 문의 | 비교리스트

계절성 인플루엔자 시장 : 역학 예측(-2028년)

Seasonal Influenza: Epidemiology Forecast to 2028

리서치사 GlobalData
발행일 2019년 10월 상품 코드 917385
페이지 정보 영문 45 Pages
가격
US $ 3,995 ₩ 4,896,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,990 ₩ 9,793,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,985 ₩ 14,690,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


계절성 인플루엔자 시장 : 역학 예측(-2028년) Seasonal Influenza: Epidemiology Forecast to 2028
발행일 : 2019년 10월 페이지 정보 : 영문 45 Pages

세계 8대 시장에서의 2018년 계절성 인플루엔자 진단 건수는 약 440만 명에 달했습니다. 하지만, 17만 9,000명이 예방 접종을 받았고, 예방 접종을 받는 인구가 증가하면서 향후 2028년까지 발병 건수는 감소할 전망입니다.

세계의 계절성 인플루엔자(Seasonal Influenza) 시장에 대해 조사했으며, 위험인자와 8대 시장 동향, 향후 10년간 예측에 대해 정리했습니다.

제1장 목차

제2장 주요 요약

제3장 역학

  • 질환의 배경
  • 위험인자와 병존 질환
  • 세계 및 역사적 동향
    • 미국
    • 유럽 5개국
    • 일본
    • 브라질
  • 예측 방법
    • 정보 출처
    • 예측 방법
  • 계절성 인플루엔자의 역학 예측
    • 진단 환자수
    • 연령별 진단 환자수
    • 성별 진단 환자수
    • 사망률
    • 연령별 예방 접종
  • 통찰
    • 역학 예측
    • 분석의 한계
    • 분석의 강점

제4장 부록

  • 참고 문헌
  • 저자에 대해
  • GlobalData에 대해
  • 연락처
LSH 19.12.12

List of Tables

  • Table 1: Risk Factors and Comorbidities for Seasonal Influenza

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, Both Sexes, All Ages, 2018 and 2028, N
  • Figure 2: Diagnosed Incidence of Lab-Confirmed Seasonal Influenza, Men, Women, All Ages, Cases per 100,000 Population, 2018
  • Figure 3: 8MM, Sources Used and Not Used for Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza
  • Figure 4: 8MM, Sources Used for Lab-Confirmed Seasonal Influenza Mortality
  • Figure 5: 8MM, Sources Used for Proportion of People Receiving Seasonal Influenza Vaccination
  • Figure 6: Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, 8MM, Both Sexes, All Ages, 2018
  • Figure 7: Age-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, 8MM, Both Sexes, All Ages, 2018, N
  • Figure 8: Sex-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza, 8MM, All Ages, 2018, N
  • Figure 9: Lab-Confirmed Seasonal Influenza Mortality, 8MM, Both Sexes, All Ages, 2018, N
  • Figure 10: Age-Specific Cases of People Receiving Seasonal Influenza Vaccination, 8MM, Both Sexes, All Ages, 2018, N

Seasonal influenza is a contagious respiratory viral illness. There are four types of seasonal influenza viruses (A, B, C, and D); however, only types A and B cause human disease of public health concern (WHO, 2014). Influenza transmission occurs when people with flu cough, sneeze, or talk and disseminate droplets. These droplets can land in the mouths or noses of people who then inhale them into the lungs (CDC, 2018).

GlobalData epidemiologists used age- and sex-specific diagnosed prevalence rates to forecast the diagnosed prevalent cases. GlobalData epidemiologists applied country-specific prevalence rates of HS, wherever available, to each country's population to obtain the number of estimated diagnosed incident cases.

The following data describes epidemiology of seasonal influenza cases. In 2018, the 8MM had 4,406,548 diagnosed incident cases of lab-confirmed seasonal influenza. This is expected to decrease to 4,285,297 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of negative 0.28%. In 2018, in the 8MM 380,179,080 people had received seasonal influenza vaccination.

This is expected to increase to 409,507,606 people receiving seasonal influenza vaccination by 2028 at an AGR of 0.77%. The variations in diagnosed incident cases of lab-confirmed influenza, and vaccination rates may be due to differences in the healthcare systems and government vaccination programs in each market. Although GlobalData epidemiologists do not expect any significant changes that would increase the vaccination rates for seasonal influenza in the 8MM, changes in vaccination guidelines and efforts to increase awareness and perception of influenza vaccination may occur and lead to an increase in vaccination uptake.

Scope:

  • The Seasonal Influenza Epidemiology Report provides an overview of the risk factors and global trends of seasonal influenza in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Brazil).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 8MM: the diagnosed incident cases of lab-confirmed seasonal influenza, lab-confirmed seasonal influenza mortality, and vaccination rates for seasonal influenza.
  • The seasonal influenza epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy:

The Seasonal Influenza Epidemiology series will allow you to -:

  • Develop business strategies by understanding the trends shaping and driving the global HS market.
  • Quantify patient populations in the global seasonal influenza market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for seasonal influenza vaccines in each of the markets covered.
  • Understand magnitude of lab-confirmed seasonal influenza mortality.
  • Quantify the population receiving seasonal influenza vaccination.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Seasonal Influenza: Executive Summary

  • 2.1. Related Reports
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global and Historical Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
    • 3.3.4. Brazil
  • 3.4. Forecast Methodology
    • 3.4.1. Sources
    • 3.4.2. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Seasonal Influenza (2018-2028)
    • 3.5.1. Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza
    • 3.5.2. Age-Specific Diagnosed Incident Cases of Disease of Lab-Confirmed Seasonal Influenza
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza
    • 3.5.4. Lab-Confirmed Seasonal Influenza Mortality
    • 3.5.5. Age-Specific Vaccination of Seasonal Influenza
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of Analysis
    • 3.6.3. Strengths of Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologist
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head and EVP of Healthcare Operations and Strategy
  • 4.3. About GlobalData
  • 4.4. Contact Us
  • 4.5. Disclaimer
Back to Top
전화 문의
F A Q